Trending...
- Primeindexer Google indexing platform launched by SEO Danmark APS
- Amicly Launches as a Safety-First Social App Designed to Help People Build Real, Meaningful Friendships
- Spokane: Water Wise Wednesday Workshops Begin March 4
SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the global urinary incontinence treatment drugs market is estimated to be valued at US$ 4,180.6 million in 2020 and is expected to exhibit a CAGR of 3.8% during the forecast period (2020-2027).
Key Trends and Analysis:
The global urinary incontinence treatment drugs market is expected to witness significant growth, owing to increasing prevalence of urinary incontinence. According to the Gothenburg Continence Research Center, in 2018, more than 423 million people suffered from urinary incontinence of which, 303 million were women.
According to the American Urological Association (AUA), in 2013, around 60%-70% of men and women suffered from urinary incontinence in the U.S.
For instance, according to American Urological Association (AUA) 2017 report, more than 200 million people worldwide were affected with stress urinary incontinence (SUI) in 2017, which can seriously affect the quality of life of both men and women. As a disease whose prevalence is related to advancing age, it affects more women than men with an approximate ratio of 3: 1.
Approval of urinary incontinence treatment drugs is also expected to drive growth of the global urinary incontinence treatment drugs market. For instance, in October 2020, Zydus Cadila received final approval from the US Food and Drug Administration (FDA) to market Solifenacin Succinate tablets, used for the treatment of overactive bladder.
Buy-Now this Research Report for detailed market insights: https://www.coherentmarketinsights.com/insight/buy-now/4400
More on Washingtoner
Key Market Takeaways:
The global urinary incontinence treatment drugs market is expected to exhibit a CAGR of 3.8% during the forecast period (2020-2027), owing to the increasing approval of drugs from regulatory authorities. For instance, in June 2019, Lupin limited announced that it received tentative approval for its Mirabegron Extended Release (ER) Tablets, 25 mg and 50 mg, from the U.S. Food and Drug Administration (FDA), to market a generic version of Myrbetriq Extended Release Tablets, 25 mg and 50 mg, of Astellas Pharma Global Development Inc. (Astellas), which is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Competitive Landscape:
Key players operating in the global urinary incontinence treatment drugs market include Johnson & Johnson, Pfizer Inc., Astellas Pharma, Inc., Allergan, Inc., Takeda Pharmaceutical Company Limited, Merck & Co., Inc., and Sanofi S.A.
Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/4400
Market Segmentation:
Related Market Intelligence Reports:
More on Washingtoner
Urinary Incontinence Treatment Devices Market, by Product (Urinary Catheters, Electrical Stimulation Devices, Artificial Urinary Sphincters, Wearable Devices, Slings (Male Slings and Female Slings), and Other Devices), by Category (Internal Urinary Incontinence Devices and External Urinary Incontinence Devices), by Incontinence (Stress Incontinence, Urge Incontinence, Overflow Incontinence, and Functional Incontinence), by End User (Clinics, Hospitals, Ambulatory surgical centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2019–2026
Read more: https://www.coherentmarketinsights.com/ongoing-insight/urinary-incontinence-treatment-devices-market-2892
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.
Key Trends and Analysis:
The global urinary incontinence treatment drugs market is expected to witness significant growth, owing to increasing prevalence of urinary incontinence. According to the Gothenburg Continence Research Center, in 2018, more than 423 million people suffered from urinary incontinence of which, 303 million were women.
According to the American Urological Association (AUA), in 2013, around 60%-70% of men and women suffered from urinary incontinence in the U.S.
For instance, according to American Urological Association (AUA) 2017 report, more than 200 million people worldwide were affected with stress urinary incontinence (SUI) in 2017, which can seriously affect the quality of life of both men and women. As a disease whose prevalence is related to advancing age, it affects more women than men with an approximate ratio of 3: 1.
Approval of urinary incontinence treatment drugs is also expected to drive growth of the global urinary incontinence treatment drugs market. For instance, in October 2020, Zydus Cadila received final approval from the US Food and Drug Administration (FDA) to market Solifenacin Succinate tablets, used for the treatment of overactive bladder.
Buy-Now this Research Report for detailed market insights: https://www.coherentmarketinsights.com/insight/buy-now/4400
More on Washingtoner
- Spokane: SPD Releases the Names of the Officers Involved in the OIS on Carlisle
- Spokane: Water Wise Wednesday Workshops Begin March 4
- Purple Heart Recipient Honored by Hall of Fame Son In Viral Tribute Sparking National Conversation on Service Fatherhood, Healing and Legacy
- Firefighters Contain Two Separate West Spokane Fires Thursday Afternoon
- Tacoma: WIAA/Gesa Credit Union Basketball Tournament
Key Market Takeaways:
The global urinary incontinence treatment drugs market is expected to exhibit a CAGR of 3.8% during the forecast period (2020-2027), owing to the increasing approval of drugs from regulatory authorities. For instance, in June 2019, Lupin limited announced that it received tentative approval for its Mirabegron Extended Release (ER) Tablets, 25 mg and 50 mg, from the U.S. Food and Drug Administration (FDA), to market a generic version of Myrbetriq Extended Release Tablets, 25 mg and 50 mg, of Astellas Pharma Global Development Inc. (Astellas), which is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Competitive Landscape:
Key players operating in the global urinary incontinence treatment drugs market include Johnson & Johnson, Pfizer Inc., Astellas Pharma, Inc., Allergan, Inc., Takeda Pharmaceutical Company Limited, Merck & Co., Inc., and Sanofi S.A.
Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/4400
Market Segmentation:
- Global Urinary Incontinence Treatment Drugs Market, By Incontinence Type:
- Urge Incontinence
- Stress Incontinence
- Over-flow Incontinence
- Mixed Incontinence
- Other Type
- Global Urinary Incontinence Treatment Drugs Market, By Drug Class:
- Anticholinergic/Antispasmodic Agents
- Skeletal Muscle Relaxants
- Antidepressants
- Alpha Blockers
- Topical Estrogens
- Others
- Global Urinary Incontinence Treatment Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Urinary Incontinence Treatment Drugs Market, By Region:
- North America
- By Country:
- U.S.
- Canada
- By Country:
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Country:
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Country:
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country:
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Country:
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Country/Region:
- North America
Related Market Intelligence Reports:
More on Washingtoner
- Amicly Launches as a Safety-First Social App Designed to Help People Build Real, Meaningful Friendships
- Primeindexer Google indexing platform launched by SEO Danmark APS
- Kaltra Introduces New Downward-Spraying Distribution Technology to Boost Microchannel Evaporator Performance
- Talentica Announces Winners of Multi-Agent Hackathon 2026
- Tacoma: Applicants Sought for the Public Utility Board
Urinary Incontinence Treatment Devices Market, by Product (Urinary Catheters, Electrical Stimulation Devices, Artificial Urinary Sphincters, Wearable Devices, Slings (Male Slings and Female Slings), and Other Devices), by Category (Internal Urinary Incontinence Devices and External Urinary Incontinence Devices), by Incontinence (Stress Incontinence, Urge Incontinence, Overflow Incontinence, and Functional Incontinence), by End User (Clinics, Hospitals, Ambulatory surgical centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2019–2026
Read more: https://www.coherentmarketinsights.com/ongoing-insight/urinary-incontinence-treatment-devices-market-2892
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.
0 Comments
Latest on Washingtoner
- 2026 Pre-Season Testing Confirms a Two-Tier Grid as Energy Management Defines Formula 1's New Era
- Platinum Car Audio LLC Focuses on Customer-Driven Vehicle Audio and Electronics Solutions
- Postmortem Pathology Expands Independent Autopsy Services in Kansas City
- Postmortem Pathology Expands Independent Autopsy Services Across Colorado
- $38 Million in U.S. Government Contract Awards Secured Through Strategic Partner. Establishing Multi-Year Defense Revenue Platform Through 2032: $BLIS
- Mecpow M1: A Safe & Affordable Laser Engraver Built for Home DIY Beginners
- CrashStory.com Launches First Colorado Crash Data Platform Built for Victims, Not Lawyers
- Tacoma: City Council Approves System Development Charges for Wastewater and Stormwater Utilities
- Tacoma: City Council Unanimously Approves Funding for HIV and STI Self-testing for LGBTQ+ Youth
- Investigation into North Spokane Fatal Stabbing Continues
- Inkdnylon Earns BBB Accreditation for Verified Business Integrity
- Josh Stout "The Western Project"
- Open House Momentum Builds at Heritage at South Brunswick
- A Celebration of Visibility, Voice and Excellence: The 57th NAACP Image Awards Golf Invitational, Presented by Wells Fargo, A PGD Global Production
- How Homeward Pet is Saving Lives Through Advanced Veterinary Medicine
- Athens in Spring: A Culinary City Break That Rivals Paris and Copenhagen
- ClearSight Therapeutics Signs LOI with Covalent Medical for $60M Multi-Channel OTC Eye Care Partnership
- Jayne Williams Joins Century Fasteners Corp. Sales and Business Development Team
- Rocket Fibre Services Growing Customer Base With netElastic Networking Software
- Cummings Graduate Institute for Behavioral Health Studies Honors New Doctor of Behavioral Health Graduates